Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pralidoxime is a small molecule antidote in the oxime class, primarily used to treat poisoning by organophosphate pesticides and nerve agents, as well as acetylcholinesterase inhibitor toxicity. Its main mechanism of action is reactivation of cholinesterase enzymes (mainly outside the central nervous system) that have been inactivated by phosphorylation due to organophosphates. By cleaving the phosphate-enzyme bond, it restores normal neuromuscular transmission and relieves paralysis of respiratory muscles. Pralidoxime also slows the "aging" process of phosphorylated cholinesterase to a nonreactivatable form and can directly detoxify certain organophosphates. It is most effective when administered soon after exposure and is typically used alongside atropine for comprehensive management[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pralidoxime.